Filing summary
Filing identity and period: The provided filing is Caladrius Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed March 5, 2020. This does not match the request metadata, which identifies Lisata Therapeutics, Inc. and “2018 Q4”; the filing itself reports annual 2019 results and comparative 2018 figures.
Business context
Caladrius is a clinical-stage biopharmaceutical company developing CD34+ cell therapies for ischemic diseases. Its principal programs were CLBS12 for critical limb ischemia in Japan, CLBS16 for coronary microvascular dysfunction in the U.S., and CLBS14 for no-option refractory disabling angina. The company had no product approved for commercial sale.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | No product-sales revenue reported | No product-sales revenue reported |
| Operating expenses | $20.1 million | $17.0 million |
| Research and development | $10.8 million | $7.6 million |
| Net loss | $19.4 million | $16.2 million |
| Net loss per share | $1.88 | $1.67 |
| Cash used in operations | $18.9 million | $20.0 million |
| Cash, cash equivalents and marketable securities at year-end | $25.2 million | $43.1 million |
Operating expenses rose 18%, primarily because R&D spending increased 42%; G&A was approximately flat. The filing reports no meaningful operating margin because the business had no product-sales revenue. Net investing cash inflow was $21.4 million in 2019, principally reflecting net sales of marketable securities; financing cash inflow was $1.2 million. Year-end working capital was approximately $20.0 million and stockholders’ equity was $20.8 million. Total liabilities were $6.6 million, including $1.0 million of operating lease liabilities; the balance sheet reports no material borrowings at year-end.
Changes, outlook and risks
- CLBS16 enrollment was completed in June 2019. Preliminary results for the first 17 of 20 patients completing six-month follow-up showed statistically significant improvements in reported measures and an acceptable safety profile; the company planned a Phase 2b study.
- CLBS12 enrollment was ongoing. Management anticipated enrollment completion in the first half of 2020 and top-line data in late 2020 or early 2021; potential Japanese approval was contingent on successful results and regulatory review.
- The company postponed initiation of the CLBS14 Phase 3 confirmatory trial pending sufficient dedicated funding. It estimated external trial costs of approximately $70 million over several years.
- Management stated existing cash was expected to fund operating expenses for at least 12 months after issuance of the financial statements, assuming CLBS14 Phase 3 initiation remained contingent on additional capital. The company expected to need substantial additional financing; failure to raise funds could force program delays, reductions or abandonment.
- Potential funding sources include equity or debt financing, partnerships, asset sales, grants and a possible New Jersey net-operating-loss sale. Equity fundraising may dilute shareholders. The NOL sale had preliminary approval only at the filing date.
- Key risks include clinical and regulatory uncertainty, patient enrollment and manufacturing constraints, dependence on third-party manufacturers without redundant suppliers, future capital needs, and commercialization, reimbursement and market-acceptance uncertainty. The filing also identified the emerging coronavirus outbreak as a possible source of trial, supply-chain and financing disruption.
- The company reported an accumulated deficit of $417.4 million and full valuation allowances against deferred tax assets. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor audited the financial statements but did not opine on internal-control effectiveness.
Most important facts to verify
- Confirm whether this is the intended issuer and reporting period: the supplied filing is Caladrius Biosciences’ 2019 Form 10-K, not a Lisata Therapeutics 2018 filing.
- Check subsequent cash use, available financing and whether the stated 12-month liquidity expectation was met.
- Verify clinical-trial progress and results for CLBS12 and CLBS16, and whether CLBS14 obtained funding and began its Phase 3 trial.
- Review potential dilution under the Lincoln Park purchase agreement and H.C. Wainwright at-the-market program, along with outstanding options and warrants.
- Assess whether manufacturing capacity, regulatory requirements, reimbursement prospects and trial disruption risks changed after the filing date.